

Making AI the center of operations

Information Technology ▶ Analyst Meet Update ▶ November 27, 2024

TARGET PRICE (Rs): 6,100

At its analyst meet, LTIMindtree (LTIM) highlighted the proliferation of AI across the value chain and the company’s readiness to capitalize on this new opportunity. AI is fundamentally transforming the way clients and system integrators are functioning, and LTIM aims to be at the forefront of this change. The company’s pivot to AI – AI in everything, everything for AI, and AI for everyone – has started reaping benefits, with AI now being a key part of the recent deal wins. The management outlined its goals—revenue of USD10bn with a strong foundation, well scaled verticals, marquee client base, deep horizontal capabilities, and strong partnerships—as being essential pillars of this journey. Along with its ~1.5x faster than industry revenue growth ambitions, LTIM continues to aspire for achieving 17-18% EBITM. Discretionary spend has not yet returned and, with the US elections now out of the way, clients will finalize their budgets in coming months; this should provide better visibility for FY26 revenue growth. We maintain REDUCE and TP of Rs6,100 at 28x Sep-26E EPS.

LTIMindtree: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	331,830	355,170	381,222	430,216	487,377
EBITDA	61,077	63,874	67,755	81,730	94,653
Adj. PAT	44,083	45,821	48,571	59,075	69,628
Adj. EPS (Rs)	149.0	154.8	164.0	199.5	235.1
EBITDA margin (%)	18.4	18.0	17.8	19.0	19.4
EBITDA growth (%)	16.4	4.6	6.1	20.6	15.8
Adj. EPS growth (%)	11.6	3.9	5.9	21.6	17.9
RoE (%)	26.6	25.0	22.6	24.0	24.6
RoIC (%)	53.8	51.5	47.8	56.0	61.7
P/E (x)	41.8	40.2	38.0	31.2	26.5
EV/EBITDA (x)	29.8	28.6	26.8	22.1	18.9
P/B (x)	11.1	9.2	8.1	7.0	6.1
FCFF yield (%)	1.2	2.6	2.3	3.0	3.4

Source: Company, Emkay Research

Pickup in deal-wins, pipeline remains healthy

In the last 18 months, LTIM has won over 45 large deals (worth more than USD25mn) with TCV of over USD2bn. More than 90% of the TCV has come from 3 key verticals—BFSI, CMT, and manufacturing & resources. The pipeline is healthy with TCV of over USD5bn, including 14 deals of over USD100mn with TCV of USD1.9bn, and 21 deals worth USD50mn-100mn with TCV of USD1.3bn. BFSI (30%), Manufacturing (33%), and CMT (31%) contribute a major portion to the pipeline. Cost optimization initiatives contribute 48% of the pipeline and vendor consolidation 17%. Transformation picked up in the last few months, led by S4 Hana and data for AI, and now forms a sizable 23% of the pipeline. Empanelment/GCCs form the balance 10%/2% of the pipeline, respectively.

AI to be key pillar of operations

The company has made a strategic pivot to AI, focusing on i) AI in everything: Infuse AI in everything the company does. ii) Everything for AI: AI at scale, engineered together. iii) AI for everyone: Empowering people, humanizing AI. AI is not only transforming the business models of the company’s clients but also the delivery models. LTIM has highlighted 6 imperatives going ahead: i) Elevating outcomes through AI. ii) Catching major spend waves. iii) Leveraging scale for growth. iv) Punching above weight in key verticals. v) Holistic investment in talent. vi) Consistent profitable growth. AI may be margin positive in the short term, but management expects AI to be margin neutral from a medium-to-long term perspective.


Aspirational target of USD10bn and 17-18% EBIT margin

The management outlined its aspirational target of reaching revenue of USD10bn from USD4.3bn in FY24. The attainment of this milestone would, however, be contingent on recovery in discretionary spending and revenue growth bouncing back to double-digits after the weakness in the last couple of years. The management is hopeful of achieving this target on an organic basis by FY32, and much earlier with acquisitions. LTIM has an ongoing margin expansion program—North Star, which focuses on 4 key areas: i) Revenue maximization – growth, value-based pricing. ii) Bending the cost curve – pyramid and average costs, right sizing in managed services. iii) Productivity – Revenue per person, AI. iv) Overheads – growing spends slower than revenue growth. LTIM aspires to reach 17-18% EBITM, contingent on revenue growth accelerating back to double digits and benefits accruing from the abovementioned initiatives.

Target Price – 12M	Sep-25
Change in TP (%)	-
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	(2.0)
CMP (26-Nov-24) (Rs)	6,227.2

Stock Data	Ticker
52-week High (Rs)	6,575
52-week Low (Rs)	4,514
Shares outstanding (mn)	296.2
Market-cap (Rs bn)	1,844
Market-cap (USD mn)	21,869
Net-debt, FY25E (Rs mn)	-29,037
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	3,506.5
ADTV-3M (USD mn)	41.6
Free float (%)	31.0
Nifty-50	24,195
INR/USD	84.3
Shareholding, Sep-24	
Promoters (%)	68.6
FPIs/MFs (%)	7.4/14.9

Price Performance			
(%)	1M	3M	12M
Absolute	5.5	8.5	13.8
Rel. to Nifty	5.4	12.1	(6.9)




Dipesh Mehta
dipeshkumar.mehta@emkayglobal.com
+91 22 6612 1253

Kevin Shah
kevin.shah@emkayglobal.com
+91 22 6612 1340


Pulkit Chawla
pulkit.chawla@emkayglobal.com
+91 22 6624 2458

Exhibit 1: Revenue growth rebounding in H1




Source: Company, Emkay Research

Exhibit 2: Weak revenue growth weighed on EBITM; salary hike to weigh on margins in Q3




Source: Company, Emkay Research

Exhibit 3: Deal intake is steady




Source: Company, Emkay Research

Exhibit 4: Steady expansion in engagements with clients across buckets




Source: Company, Emkay Research

Exhibit 5: Building on its strong foundation, to accelerate growth



Source: Company, Emkay Research

Exhibit 6: Strategic pivot to AI with monetizing plan



Source: Company, Emkay Research

Exhibit 7: Turbocharged portfolio to drive toward the company’s aspirational USD10bn revenue target




Source: Company, Emkay Research

Exhibit 8: Strategic initiative for driving growth



Source: Company, Emkay Research

Exhibit 9: Scaling AI-driven delivery in IT operations and engineering



Source: Company, Emkay Research

Exhibit 10: Everything for AI – The company is building new offerings to capture new opportunities



Source: Company, Emkay Research

Exhibit 11: Company’s deep capabilities having a positive impact




Source: Company, Emkay Research

Exhibit 12: Three phases for achieving the USD10bn target



Source: Company, Emkay Research

Exhibit 13: LTIM – One-year forward PER



Source: Company, Emkay Research

LTIMindtree: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	331,830	355,170	381,222	430,216	487,377
Revenue growth (%)	27.1	7.0	7.3	12.9	13.3
EBITDA	61,077	63,874	67,755	81,730	94,653
EBITDA growth (%)	16.4	4.6	6.1	20.6	15.8
Depreciation & Amortization	7,227	8,189	9,749	10,262	10,909
EBIT	53,850	55,685	58,007	71,469	83,744
EBIT growth (%)	15.8	3.4	4.2	23.2	17.2
Other operating income	1,504	2,217	2,699	2,677	2,749
Other income	5,569	7,019	9,797	10,023	11,902
Financial expense	1,504	2,217	2,699	2,677	2,749
PBT	57,915	60,487	65,104	78,815	92,897
Extraordinary items	0	0	0	0	0
Taxes	13,812	14,641	16,502	19,704	23,224
Minority interest	20	25	31	36	45
Income from JV/Associates	0	0	0	0	0
Reported PAT	44,083	45,821	48,571	59,075	69,628
PAT growth (%)	11.7	3.9	6.0	21.6	17.9
Adjusted PAT	44,083	45,821	48,571	59,075	69,628
Diluted EPS (Rs)	149.0	154.8	164.0	199.5	235.1
Diluted EPS growth (%)	11.6	3.9	5.9	21.6	17.9
DPS (Rs)	60.0	65.0	67.0	84.0	98.0
Dividend payout (%)	40.3	42.0	40.9	42.1	41.7
EBITDA margin (%)	18.4	18.0	17.8	19.0	19.4
EBIT margin (%)	16.2	15.7	15.2	16.6	17.2
Effective tax rate (%)	23.8	24.2	25.3	25.0	25.0
NOPLAT (pre-IndAS)	41,007	42,206	43,304	53,602	62,808
Shares outstanding (mn)	295.8	295.9	296.2	296.2	296.2

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
PBT	57,915	60,487	65,104	78,815	92,897
Others (non-cash items)	5,893	5,940	9,749	10,262	10,909
Taxes paid	(15,217)	(15,707)	(16,502)	(19,704)	(23,224)
Change in NWC	(17,645)	5,975	(6,749)	(5,128)	(7,366)
Operating cash flow	30,946	56,695	51,601	64,245	73,215
Capital expenditure	(9,346)	(8,330)	(8,520)	(9,720)	(11,220)
Acquisition of business	(1,486)	(59)	0	0	0
Interest & dividend income	1,266	2,573	0	0	0
Investing cash flow	(3,309)	(39,121)	(20,920)	(29,720)	(31,220)
Equity raised/(repaid)	2	12	0	0	0
Debt raised/(repaid)	71	(280)	0	0	0
Payment of lease liabilities	(3,388)	(3,761)	0	0	0
Interest paid	(375)	(906)	0	0	0
Dividend paid (incl tax)	(15,627)	(17,753)	(19,844)	(24,879)	(29,026)
Others	0	0	0	0	0
Financing cash flow	(19,317)	(22,688)	(19,844)	(24,879)	(29,026)
Net chg in Cash	8,320	(5,114)	10,837	9,645	12,969
OCF	30,946	56,695	51,601	64,245	73,215
Adj. OCF (w/o NWC chg.)	48,591	50,720	58,351	69,373	80,581
FCFF	21,600	48,365	43,081	54,525	61,995
FCFE	21,362	48,721	40,382	51,848	59,246
OCF/EBITDA (%)	50.7	88.8	76.2	78.6	77.4
FCFE/PAT (%)	48.5	106.3	83.1	87.8	85.1
FCFF/NOPLAT (%)	52.7	114.6	99.5	101.7	98.7

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	296	296	296	296	296
Reserves & Surplus	165,625	199,876	228,603	262,799	303,400
Net worth	165,921	200,172	228,899	263,095	303,696
Minority interests	71	92	123	159	204
Deferred tax liability (net)	(3,662)	(2,063)	(2,063)	(2,063)	(2,063)
Total debt	0	0	0	0	0
Total liabilities & equity	162,330	198,201	226,959	261,191	301,837
Net tangible fixed assets	9,697	16,555	15,744	15,678	15,721
Net intangible assets	3,560	3,151	2,896	2,533	2,179
Net ROU assets	12,539	19,013	18,850	18,737	19,360
Capital WIP	8,126	4,669	4,669	4,669	4,669
Goodwill	11,892	11,927	11,927	11,927	11,927
Investments [JV/Associates]	54,622	87,502	99,902	119,902	139,902
Cash & equivalents	23,389	18,200	29,037	38,683	51,651
Current assets (ex-cash)	107,327	112,363	124,490	138,134	154,036
Current Liab. & Prov.	68,822	75,179	80,557	89,073	97,608
NWC (ex-cash)	38,505	37,184	43,933	49,062	56,428
Total assets	162,330	198,201	226,959	261,191	301,837
Net debt	(23,389)	(18,200)	(29,037)	(38,683)	(51,651)
Capital employed	162,330	198,201	226,959	261,191	301,837
Invested capital	76,193	87,830	93,351	97,937	105,615
BVPS (Rs)	560.9	676.5	772.8	888.3	1,025.4
Net Debt/Equity (x)	(0.1)	(0.1)	(0.1)	(0.1)	(0.2)
Net Debt/EBITDA (x)	(0.4)	(0.3)	(0.4)	(0.5)	(0.5)
Interest coverage (x)	0.0	0.0	0.0	0.0	0.0
RoCE (%)	36.6	34.8	31.9	33.4	34.0

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	41.8	40.2	38.0	31.2	26.5
P/CE(x)	35.9	34.1	31.6	26.6	22.9
P/B (x)	11.1	9.2	8.1	7.0	6.1
EV/Sales (x)	5.5	5.1	4.8	4.2	3.7
EV/EBITDA (x)	29.8	28.6	26.8	22.1	18.9
EV/EBIT(x)	33.8	32.8	31.3	25.3	21.4
EV/IC (x)	23.9	20.8	19.4	18.4	17.0
FCFF yield (%)	1.2	2.6	2.3	3.0	3.4
FCFE yield (%)	1.2	2.6	2.2	2.8	3.2
Dividend yield (%)	1.0	1.0	1.1	1.3	1.6
DuPont-RoE split					
Net profit margin (%)	13.3	12.9	12.7	13.7	14.3
Total asset turnover (x)	2.0	2.0	1.8	1.8	1.7
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0
RoE (%)	26.6	25.0	22.6	24.0	24.6
DuPont-RoIC					
NOPLAT margin (%)	12.4	11.9	11.4	12.5	12.9
IC turnover (x)	4.4	4.3	4.2	4.5	4.8
RoIC (%)	53.8	51.5	47.8	56.0	61.7
Operating metrics					
Core NWC days	42.4	38.2	42.1	41.6	42.3
Total NWC days	42.4	38.2	42.1	41.6	42.3
Fixed asset turnover	8.8	8.0	7.6	8.8	9.9
Opex-to-revenue (%)	81.6	82.0	82.2	81.0	80.6


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
18-Oct-24	5,992	6,100	Reduce	Dipeshkumar Mehta
01-Oct-24	6,273	6,100	Reduce	Dipeshkumar Mehta
17-Jul-24	5,562	5,250	Reduce	Dipeshkumar Mehta
01-Jul-24	5,448	5,250	Reduce	Dipeshkumar Mehta
03-Jun-24	4,649	5,000	Reduce	Dipeshkumar Mehta
27-May-24	4,892	5,000	Reduce	Dipeshkumar Mehta
25-Apr-24	4,635	5,000	Reduce	Dipeshkumar Mehta
31-Mar-24	4,938	5,100	Reduce	Dipeshkumar Mehta
01-Mar-24	5,274	5,900	Reduce	Dipeshkumar Mehta
18-Jan-24	5,603	5,900	Reduce	Dipeshkumar Mehta
31-Dec-23	6,295	6,250	Reduce	Dipeshkumar Mehta
30-Nov-23	5,537	5,500	Reduce	Dipeshkumar Mehta
19-Oct-23	5,458	5,500	Hold	Dipeshkumar Mehta
02-Oct-23	5,210	5,600	Hold	Dipeshkumar Mehta
17-Jul-23	5,135	4,950	Hold	Dipeshkumar Mehta
02-Jul-23	5,197	4,950	Hold	Dipeshkumar Mehta
28-Apr-23	4,419	4,750	Hold	Dipeshkumar Mehta
01-Apr-23	4,760	4,850	Hold	Dipeshkumar Mehta
15-Mar-23	4,592	4,850	Hold	Dipeshkumar Mehta
21-Jan-23	4,268	4,600	Hold	Dipeshkumar Mehta
02-Jan-23	4,322	4,700	Hold	Dipeshkumar Mehta
12-Dec-22	4,331	4,700	Hold	Dipeshkumar Mehta
15-Oct-22	4,669	4,500	Hold	Dipeshkumar Mehta
04-Oct-22	4,588	4,450	Hold	Dipeshkumar Mehta
15-Jul-22	3,975	4,700	Buy	Dipeshkumar Mehta
23-Jun-22	4,133	4,700	Buy	Dipeshkumar Mehta
07-May-22	4,593	-	UR	Dipeshkumar Mehta
20-Apr-22	5,170	6,350	Hold	Dipeshkumar Mehta
01-Apr-22	6,174	6,500	Hold	Dipeshkumar Mehta
22-Feb-22	5,991	6,500	Hold	Dipeshkumar Mehta
20-Jan-22	6,606	6,800	Hold	Dipeshkumar Mehta
01-Jan-22	7,332	6,650	Hold	Dipeshkumar Mehta
09-Dec-21	6,606	6,650	Hold	Dipeshkumar Mehta
30-Nov-21	6,810	6,650	Hold	Dipeshkumar Mehta

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm’s length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative’s may have Financial Interest/proprietary positions in the securities recommended in this report as of November 27, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative’s may have material conflict of interest in the securities recommended in this report as of November 27, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative’s may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 27, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.